Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Trading 05-20 10:35:40 EDT

5.82

+0.06

+0.95%

High5.86	Low5.64	Vol355.45K
Open5.68	D1 Closing5.76	Amplitude3.82%
Mkt Cap829.59M	Tradable Cap739.03M	Total Shares142.66M
T/O2.05M	T/O Rate0.28%	Tradable Shares127.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":5.815,"timestamp":1716215729531,"preClose":5.76,"halted":0,"volume":355448,"delay":0,"floatShares":127090318,"shares":142663526,"eps":-0.435739,"marketStatus":"Trading","change":0.055,"latestTime":"05-20 10:35:40 EDT","open":5.68,"high":5.86,"low":5.64,"amount":2045336.5118208,"amplitude":0.038194,"askPrice":5.82,"askSize":291,"bidPrice":5.81,"bidSize":1869,"shortable":3,"etf":0,"ttmEps":-0.435739,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716235200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":5.76,"preHourTrading":{"tag":"盘前","latestPrice":5.69,"preClose":5.76,"latestTime":"09:29 EDT","volume":1377,"amount":7848.3691665,"timestamp":1716211799999},"postHourTrading":{"tag":"盘后","latestPrice":5.7,"preClose":5.76,"latestTime":"19:11 EDT","volume":18883,"amount":108735.8,"timestamp":1715987511790},"volumeRatio":1.150269},"requestUrl":"/m/hq/s/AUPH/wiki","defaultTab":"wiki","newsList":[{"id":"2435964875","title":"Aurinia’s LUPKYNIS Deemed Cost-Effective for Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2435964875","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435964875?lang=en_us&edition=fundamental","pubTime":"2024-05-14 18:38","pubTimestamp":1715683104,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals Inc. announced that their drug LUPKYNIS is a cost-effective treatmen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinias-lupkynis-deemed-cost-effective-for-lupus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinias-lupkynis-deemed-cost-effective-for-lupus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435950955","title":"Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2435950955","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435950955?lang=en_us&edition=fundamental","pubTime":"2024-05-14 18:00","pubTimestamp":1715680800,"startTime":"0","endTime":"0","summary":"An updated analysis showed that LUPKYNIS is a cost-effective treatment for lupus nephritis, on par with other interventions for diabetes, blood pressure, and hyperlipidemia in adult patients with active lupus nephritis .Additional data on baseline demographics from the Enlight-LN registry and safety and efficacy data of LUPKYNIS will also be presented.Moreover, in a smaller subgroup analysis of Black, Hispanic, and Latino patients — a population disproportionately affected by LN — cost-effectiveness was on par with other interventions for diabetes, blood pressure, and hyperlipidemia. The incremental cost of the treatment per QALY was $77,436 and was $67,828 per evLYG in Black, Hispanic, and Latino patients.\"People living with lupus nephritis must be able to access clinically meaningful treatment options to manage the severity of the dis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tryqhmXnB2LWhfbKRQXf8Q--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/244520aa3ab8f9dd30c9c2d10c6263d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tryqhmXnB2LWhfbKRQXf8Q--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/244520aa3ab8f9dd30c9c2d10c6263d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysis-showing-lupkynis-cost-effective-100000492.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434409178","title":"Aurinia Highlights LUPKYNIS Success in Lupus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2434409178","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434409178?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:21","pubTimestamp":1715257302,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals showcased data at the Congress of Clinical Rheumatology East 2024, e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupkynis-success-in-lupus-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupkynis-success-in-lupus-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434096999","title":"BRIEF-Aurinia Presents Data Reinforcing Lupkynis® Safety And Efficacy For People With Lupus Nephritis At Congress Of Clinical Rheumatology East 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434096999","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434096999?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:45","pubTimestamp":1715255110,"startTime":"0","endTime":"0","summary":"May 9 (Reuters) - Aurinia Pharmaceuticals Inc   :   * AURINIA PRESENTS DATA REINFORCING LUPKYNIS® SAFETY AND EFFICACY FOR PEOPLE WITH LUPUS NEPHRITIS AT CONGRESS OF CLINICAL RHEUMATOLOGY EAST 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434509850","title":"Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434509850","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434509850?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:00","pubTimestamp":1715248800,"startTime":"0","endTime":"0","summary":"A propensity analysis of ALMS, AURA-LV, and AURORA 1 suggested that initial therapy with LUPKYNIS plus standard of care reduced exposure to potential toxicities and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids alone.A propensity analysis of the Aspreva Lupus Management Study , AURA-LV, and AURORA 1 studies suggested that LUPKYNIS plus standard of care demonstrated superior reductions in proteinuria and reduced patient exposure to toxicities compared with higher doses of mycophenolate mofetil  and glucocorticoids or cyclophosphamide and glucocorticoids alone. Safety and efficacy outcomes for propensity-matched patients with active LN from the AURA-LV plus AURORA 1 studies were assessed at three and six months. Patients who received the LUPKYNIS-based regimen experienced reductions in exposure to glucocorticoids and more patients achieved a >50% urine protein creatinine ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FkN.0fyCc7JD3kPFwj9GxA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/534f06ae96ec36a3f25312ac804ee1eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FkN.0fyCc7JD3kPFwj9GxA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/534f06ae96ec36a3f25312ac804ee1eb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-presents-data-reinforcing-lupkynis-100000866.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433275106","title":"Aurinia Pharmaceuticals to Engage at RBC Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2433275106","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433275106?lang=en_us&edition=fundamental","pubTime":"2024-05-07 18:37","pubTimestamp":1715078246,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals Inc. has announced participation in the upcoming 2024 RBC Capital Ma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-to-engage-at-rbc-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-to-engage-at-rbc-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433936220","title":"BRIEF-Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2433936220","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433936220?lang=en_us&edition=fundamental","pubTime":"2024-05-07 18:08","pubTimestamp":1715076537,"startTime":"0","endTime":"0","summary":"May 7 (Reuters) - Aurinia Pharmaceuticals Inc   :   * AURINIA WILL ATTEND 2024 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432184302","title":"Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2432184302","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2432184302?lang=en_us&edition=fundamental","pubTime":"2024-05-04 01:02","pubTimestamp":1714755767,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17. AUPH isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Greetings, and welcome to the Aurinia Pharmaceuticals First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the conference over to Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Please go ahead, Andrea.Peter Greenleaf: Thanks, Andrea, and good morning, everyone. I want to thank everybody for joining us on today's call. On this morning's call, we will focus on the company's first quarter performance. I'll then turn the call over to Joe Miller, our CFO, to provide additional details on our financial results. We saw ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GTk8pBwptQji5kKoRU0ncw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/fddf0407aa72c4ce93d71741721a700e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GTk8pBwptQji5kKoRU0ncw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/fddf0407aa72c4ce93d71741721a700e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-inc-nasdaq-auph-170247658.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432492404","title":"Aurinia Pharmaceuticals’ LUPKYNIS: A Strong Buy on Surging Sales and Positive Market Indicators","url":"https://stock-news.laohu8.com/highlight/detail?id=2432492404","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432492404?lang=en_us&edition=fundamental","pubTime":"2024-05-03 18:36","pubTimestamp":1714732573,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ed Arce has maintained their bullish stance on AUPH stock, giving a Buy rating yesterday. Ed Arce has given his Buy rating ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-lupkynis-a-strong-buy-on-surging-sales-and-positive-market-indicators?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-lupkynis-a-strong-buy-on-surging-sales-and-positive-market-indicators?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432006959","title":"Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432006959","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432006959?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:49","pubTimestamp":1714682989,"startTime":"0","endTime":"0","summary":"AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter.AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 wh","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157508130/image_157508130.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157508130/image_157508130.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688722-aurinia-pharma-a-welcome-change-to-the-thesis","is_publish_highlight":false,"gpt_icon":0},{"id":"2432603885","title":"Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2432603885","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432603885?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:10","pubTimestamp":1714648209,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 82.35%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.18 per share when it actually produced a loss of $0.19, delivering a surprise of -5.56%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Aurinia , which belongs to the Zacks Medical - Drugs industry, posted revenues of $50.3 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 8.65%. This compares to year-ago revenues of $34.41 million. The company has topped consensus revenue estimates four times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the pe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-auph-reports-q1-111009363.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432274076","title":"Aurinia Pharma GAAP EPS of -$0.07 beats by $0.07, revenue of $50.3M beats by $3.23M","url":"https://stock-news.laohu8.com/highlight/detail?id=2432274076","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432274076?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:09","pubTimestamp":1714644577,"startTime":"0","endTime":"0","summary":"Aurinia Pharma press release  (NASDAQ:AUPH): Q1  GAAP EPS of -$0.07  beats by $0.07.\nRevenue of $50.3M (+46.2% Y/Y)  beats by $3.23M.\nCompany reiterates 2024 net product revenue guidance of $200 to $220 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098235-aurinia-pharma-gaap-eps-of-0_07-beats-0_07-revenue-of-50_3m-beats-3_23m","is_publish_highlight":false,"gpt_icon":0},{"id":"2432562215","title":"Aurinia Pharmaceuticals Q1 2024 GAAP EPS $(0.07) Beats $(0.14) Estimate, Sales $50.300M Beat $47.453M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2432562215","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432562215?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:01","pubTimestamp":1714644063,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.14) by 50 percent.  The company reported quarterly sales of $50.300 million which beat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38575505/aurinia-pharmaceuticals-q1-2024-gaap-eps-0-07-beats-0-14-estimate-sales-50-300m-beat-47-453m-estima","is_publish_highlight":false,"gpt_icon":0},{"id":"2432627261","title":"Press Release: Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432627261","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432627261?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:00","pubTimestamp":1714644000,"startTime":"0","endTime":"0","summary":"--  Achieved $50.3 million in total net revenue and $48.1 million in net. product revenue for the first quarter of 2024, representing year over. year growth of approximately 46% and 40% respectively, and extending the. --  Rapidly completed restructuring while maintaining focus on commercial. excluding share repurchases, in second quarter 2024, with estimated cost. \"We are pleased to be on track to reach positive free cash flows, excluding share repurchases, in the second quarter of 2024, ahead of prior projections, further strengthening our financial position, and with further balance sheet growth, allowing more strategic flexibility for the Company,\" said Peter Greenleaf, President and Chief Executive Officer of Aurinia. \"We recently achieved several key milestones, including FDA approval of a label update for LUPKYNIS which now includes long-term efficacy data from our AURORA Clinical Program. We have also launched an innovative new marketing campaign to further educate rheumatologi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432454606","title":"Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432454606","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432454606?lang=en_us&edition=fundamental","pubTime":"2024-05-02 14:22","pubTimestamp":1714630966,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report), Aurinia P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bridgebio-pharma-bbio-aurinia-pharmaceuticals-auph-and-908-devices-mass?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bridgebio-pharma-bbio-aurinia-pharmaceuticals-auph-and-908-devices-mass?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432454446","title":"Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432454446","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432454446?lang=en_us&edition=fundamental","pubTime":"2024-05-02 14:20","pubTimestamp":1714630849,"startTime":"0","endTime":"0","summary":"In a report released on April 30, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-aurinia-pharmaceuticals-auph?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432194523","title":"BRIEF-Aurinia Underscores Enduring Commitment To People Living With Lupus Nephritis Through Innovative Advocacy And Education Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2432194523","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432194523?lang=en_us&edition=fundamental","pubTime":"2024-05-01 18:09","pubTimestamp":1714558166,"startTime":"0","endTime":"0","summary":"May 1  - Aurinia Pharmaceuticals Inc   :   * AURINIA UNDERSCORES ENDURING COMMITMENT TO PEOPLE LIVING WITH LUPUS NEPHRITIS THROUGH INNOVATIVE ADVOCACY AND EDUCATION INITIATIVES FOR LUPUS AWARENESS MONTHSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432526638","title":"Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2432526638","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432526638?lang=en_us&edition=fundamental","pubTime":"2024-05-01 18:00","pubTimestamp":1714557600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, May 01, 2024----In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc.  , today announced several initiatives to improve understanding of the seriousness of lupus nephritis  and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.Aurinia is on a mission to tackle the toughest challenges that the LN community faces through collaborative efforts with key stakeholders across the healthcare ecosystem, including patients, healthcare professionals , and policymakers. Through awareness, education, advocacy, and partnerships with the LN community, the Aurinia team is working to help eliminate barriers to access, promote equity, and improve health outcomes for those impacted by LN.Advocacy EventsAs a dedicated partner to the LN community, Aurinia participates in events across the country throughout the year to promote awareness and uplift the people li","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Msotv3wKKl41VAUjyCfLUA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ce14c5f9a2e8a6a7f4693d5c53cdbdbb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Msotv3wKKl41VAUjyCfLUA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ce14c5f9a2e8a6a7f4693d5c53cdbdbb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-underscores-enduring-commitment-people-100000683.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431428083","title":"Aurinia gains on Lupkynis label update","url":"https://stock-news.laohu8.com/highlight/detail?id=2431428083","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431428083?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:42","pubTimestamp":1714480954,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  traded higher premarket Tuesday after the Canadian biotech announced that the U.S. Food and Drug Administration  approved label updates favoring the administration of its lead product, Lupkynis. The company said that with the new update, monthly kidney function assessments will no longer be required after the first year of Lupkynis therapy.  Also known as voclosporin, Lupkynis is an oral medicine indicated in the U.S. and EU for the autoimmune disorder lupus nephritis. Instead, patients on Lupkynis will be required to undergo a kidney function test called eGFR every three months. Reflecting three-year data from Aurinia’s  Phase 3 long-term extension trial, AURORA 2, the update no longer requires the company to provide language suggesting that the drug’s effects haven’t been established beyond one year.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096201-aurinia-stock-gains-lupkynis-label-update","is_publish_highlight":false,"gpt_icon":0},{"id":"2431196573","title":"Aurinia’s LUPKYNIS Wins FDA Label Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2431196573","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2431196573?lang=en_us&edition=fundamental","pubTime":"2024-04-30 18:37","pubTimestamp":1714473477,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals announced that the FDA has approved an updated label for LUPKYNIS to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinias-lupkynis-wins-fda-label-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinias-lupkynis-wins-fda-label-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.1474},{"period":"1month","weight":0.1731},{"period":"3month","weight":-0.0154},{"period":"6month","weight":-0.3302},{"period":"1year","weight":-0.4637},{"period":"ytd","weight":-0.3593}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106403},{"month":2,"riseRate":0.5,"avgChangeRate":0.009372},{"month":3,"riseRate":0.4,"avgChangeRate":0.102117},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012088},{"month":5,"riseRate":0.6,"avgChangeRate":0.002586},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.039513},{"month":7,"riseRate":0.555556,"avgChangeRate":0.03731},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.068337},{"month":9,"riseRate":0.444444,"avgChangeRate":0.078247},{"month":10,"riseRate":0.6,"avgChangeRate":0.041208},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001599},{"month":12,"riseRate":0.4,"avgChangeRate":0.111111}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}